Amgen has acquired Dezima Pharma, a biotechnology company developing drugs to treat cardiovascular disease from Forbion Capital for as much as $1.6 billion.   Dezima was founded in 2012 by Prof. John Kastelein, Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, The Netherlands. Amgen gains its TA-8995 oral, once-daily CETP inhibitor in development for use in patients with mild dyslipidemia. TA-8995, both as monotherapy and ...